Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A quantitative approach to benefit-risk assessment of medicines - part 1: The development of a new model using multi-criteria decision analysis

Mussen, Filip, Salek, Mir-saeed and Walker, Stuart 2007. A quantitative approach to benefit-risk assessment of medicines - part 1: The development of a new model using multi-criteria decision analysis. Pharmacoepidemiology and Drug Safety 16 (S1) , s2-s15. 10.1002/pds.1435

Full text not available from this repository.

Abstract

Purpose One of the most important uses of benefit-risk assessment pertains to approval of new medicines by regulatory authorities and the subsequent review of these products during their life-cycle when new safety and/or efficacy data becomes available. At present, there exist no validated, well-accepted models for benefit-risk assessment that have the appropriate degree of sophistication, and as a consequence no models are widely used by regulatory authorities or industry. The aim of the study was therefore to develop a new model for benefit-risk assessment of medicines using multi-criteria decision analysis (MCDA). Methods The MCDA methodology was used for a systematic approach to assess the benefit risk ratio of medicines. The reasons for adopting this approach were (1) taking multiple benefit and risk criteria into account, (2) making a judgement on the evidence and potential uncertainty because of the incompleteness of evidence, and (3) making trade-offs of the benefits against risks. Results It was demonstrated through a seven-step approach how MCDA is used to construct the model. Ten benefit and ten risk criteria were identified to form a value tree. Then fixed scales were established for all criteria and options on the criteria were scored. Weights were assigned for each criteria using swing-weighting. Finally sensitivity analysis was carried. Conclusions This novel approach based on MCDA has the potential for being applied as a new tool for judging and deciding on the benefits and risks, thereby helping regulators and industry in the development and approval of new medicines and their adequate use. Copyright

Item Type: Article
Date Type: Publication
Status: Published
Schools: Pharmacy
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Benefit-risk ; Model ; Multi-criteria decision analysis (MCDA)
ISSN: 1099-1557
Last Modified: 01 Feb 2022 10:26
URI: https://orca.cardiff.ac.uk/id/eprint/986

Citation Data

Cited 95 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item